

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)
(the "**Company**")

UPDATE ANNOUNCEMENT

The Board of Directors of the Company (the "**Board**") refers to the Company's announcement on 8 September 2015 as well as the circular dated 26 August 2015 to shareholders of the Company (the "**Shareholders**") in relation to the proposed disposal (the "**Proposed Disposal**") to Golden Meditech Holdings Limited (the "**Purchaser**") of the Company's 7,314,015 ordinary shares in China Cord Blood Corporation ("**CCBC**") and 7% senior unsecured convertible note due 2017 issued by CCBC to the Company (collectively, the "**Assets**").

The Board refers Shareholders to the voluntary announcement made by the Purchaser on the HKExnews earlier today wherein the Purchaser informed its shareholders and potential investors that it intends to proceed with its acquisition of the Assets from the Company after all the conditions precedents set forth in the conditional purchase agreement dated 8 May 2015 entered into between the Company and the Purchaser in relation to the sale and purchase of the Assets have been fulfilled (or waived, if applicable). A copy of the Purchaser's announcement is annexed to this announcement.

Shareholders are reminded of the upcoming extraordinary general meeting to be held at Auditorium 302, Level 3, NTU@one-north Executive Centre, 11 Slim Barracks Rise (off North Buona Vista Road), Singapore 138664 on Monday, 14 September 2015 at 3 p.m. for the purpose of seeking Shareholders' approval for the Proposed Disposal.

By Order of the Board

CORDLIFE GROUP LIMITED

Mr. Yee Pinh Jeremy
Director
10 September 2015

ANNEX

PURCHASER'S ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Golden Meditech Holdings Limited

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 00801)

**VOLUNTARY ANNOUNCEMENT
IN RELATION TO
THE ACQUISITION OF THE CONVERTIBLE NOTES AND
9.13% OF THE ISSUED SHARE CAPITAL OF
CHINA CORD BLOOD CORPORATION
FROM CORDLIFE GROUP LIMITED**

This is a voluntary announcement made by Golden Meditech Holdings Limited (the “**Company**”).

Reference is made to the announcements of the Company dated 8 May 2015 in relation to, among other things, the proposed major transaction in relation to the acquisition of the convertible notes and 9.13% of the issued share capital of China Cord Blood Corporation from Cordlife Group Limited and dated 6 August 2015 in relation to the delay in despatch of the circular of the Company with regard to, among other things, the CGL Acquisition. Terms defined in the aforesaid announcements shall have the same meanings when used herein unless the context requires otherwise.

As the Company has recently received various enquiries in relation to the status of the CGL Acquisition, the Board would like to inform the Shareholders and potential investors that the Company intends to proceed with the CGL Acquisition after all the conditions precedent set forth in the CGL Agreement have been fulfilled (or waived, if applicable). The circular, which contains relevant information with respect to the CGL Acquisition, is currently under pre-vetting by the relevant regulator. The circular will be published and despatched to Shareholders as soon as possible after it has been finalised.

The CGL Completion is subject to the fulfilment (or waiver, where applicable) of the conditions precedent set out in the CGL Agreement. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Golden Meditech Holdings Limited
Kam Yuen
Chairman

Hong Kong, 10 September 2015

As at the date of this announcement, the Board comprises 9 Directors. The executive Directors are Mr. Kam Yuen (Chairman), Mr. Kong Kam Yu and Mr. Yu Kwok Kuen, Harry; the non-executive Directors are Ms. Zheng Ting and Mr. Gao Yue; and the independent non-executive Directors are Prof. Cao Gang, Mr. Feng Wen, Prof. Gu Qiao and Mr. Daniel Foa.